Guardian Pharmacy [GRDN] vs National Healthcare [NHC] Detailed Stock Comparison
Guardian Pharmacy
NYSE
Loading...
National Healthcare
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Guardian Pharmacy wins in 5 metrics, National Healthcare wins in 13 metrics, with 0 ties. National Healthcare appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Guardian Pharmacy | National Healthcare | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 90.13 | 18.11 | National Healthcare |
| Price-to-Book Ratio | 8.94 | 1.84 | National Healthcare |
| Debt-to-Equity Ratio | 22.18 | 16.83 | National Healthcare |
| PEG Ratio | -6.39 | -1.50 | Guardian Pharmacy |
| EV/EBITDA | -41.96 | 11.20 | Guardian Pharmacy |
| Profit Margin (TTM) | -5.19% | 7.19% | National Healthcare |
| Operating Margin (TTM) | 4.38% | 9.09% | National Healthcare |
| EBITDA Margin (TTM) | 4.38% | 9.09% | National Healthcare |
| Return on Equity | -52.74% | 10.66% | National Healthcare |
| Return on Assets (TTM) | -10.92% | 5.02% | National Healthcare |
| Free Cash Flow (TTM) | $41.59M | $79.70M | National Healthcare |
| Dividend Yield | N/A | 2.30% | N/A |
| 1-Year Return | 37.90% | -1.38% | Guardian Pharmacy |
| Price-to-Sales Ratio (TTM) | 1.14 | 1.29 | Guardian Pharmacy |
| Enterprise Value | $1.55B | $1.80B | National Healthcare |
| EV/Revenue Ratio | 1.17 | 1.23 | Guardian Pharmacy |
| Gross Profit Margin (TTM) | 19.79% | 39.58% | National Healthcare |
| Revenue per Share (TTM) | $21 | $94 | National Healthcare |
| Earnings per Share (Diluted) | $-1.48 | $6.70 | National Healthcare |
| Beta (Stock Volatility) | N/A | 0.59 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Guardian Pharmacy vs National Healthcare Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Guardian Pharmacy | -0.84% | -7.96% | -15.73% | 14.82% | 11.14% | 20.36% |
| National Healthcare | -2.37% | -4.03% | 8.08% | 11.88% | 30.00% | 13.94% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Guardian Pharmacy | 37.90% | 34.87% | 34.87% | 34.87% | 34.87% | 34.87% |
| National Healthcare | -1.38% | 98.89% | 85.59% | 89.80% | 229.32% | 242.71% |
News Based Sentiment: Guardian Pharmacy vs National Healthcare
Guardian Pharmacy
News based Sentiment: MIXED
Guardian Pharmacy Services had a month of contrasts, with strong Q2 financial results and positive analyst coverage offset by significant insider selling and valuation concerns. The raised guidance and operational improvements are encouraging, but the insider activity and DCF valuation create uncertainty for investors.
National Healthcare
News based Sentiment: MIXED
October saw significant institutional investment in NHC, which is a positive sign, but this was counterbalanced by a lease default notice and mixed stock performance. The dividend provides stability, but the overall picture is complex, making it a moderately important month for investors.
Performance & Financial Health Analysis: Guardian Pharmacy vs National Healthcare
| Metric | GRDN | NHC |
|---|---|---|
| Market Information | ||
| Market Cap | $1.52B | $1.91B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 319,010 | 76,840 |
| 90 Day Avg. Volume | 397,023 | 73,717 |
| Last Close | $23.74 | $118.44 |
| 52 Week Range | $16.50 - $30.39 | $89.14 - $136.86 |
| % from 52W High | -21.88% | -13.46% |
| All-Time High | $30.39 (Sep 12, 2025) | $138.49 (Jul 29, 2024) |
| % from All-Time High | -21.88% | -14.48% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.29% |
| Quarterly Earnings Growth | -0.15% | -0.12% |
| Financial Health | ||
| Profit Margin (TTM) | -0.05% | 0.07% |
| Operating Margin (TTM) | 0.04% | 0.09% |
| Return on Equity (TTM) | -0.53% | 0.11% |
| Debt to Equity (MRQ) | 22.18 | 16.83 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.68 | $65.93 |
| Cash per Share (MRQ) | $0.30 | $16.62 |
| Operating Cash Flow (TTM) | $57.66M | $149.07M |
| Levered Free Cash Flow (TTM) | $87.15M | $100.15M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.30% |
| Last 12-Month Dividend | N/A | $2.44 |
Valuation & Enterprise Metrics Analysis: Guardian Pharmacy vs National Healthcare
| Metric | GRDN | NHC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 90.13 | 18.11 |
| Forward P/E | 27.52 | 282.14 |
| PEG Ratio | -6.39 | -1.50 |
| Price to Sales (TTM) | 1.14 | 1.29 |
| Price to Book (MRQ) | 8.94 | 1.84 |
| Market Capitalization | ||
| Market Capitalization | $1.52B | $1.91B |
| Enterprise Value | $1.55B | $1.80B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.17 | 1.23 |
| Enterprise to EBITDA | -41.96 | 11.20 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.59 |
| Book Value per Share (MRQ) | $2.68 | $65.93 |
Financial Statements Comparison: Guardian Pharmacy vs National Healthcare
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GRDN | NHC |
|---|---|---|
| Revenue/Sales | $329.31M | $373.70M |
| Cost of Goods Sold | $264.96M | $228.13M |
| Gross Profit | $64.35M | $145.57M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $13.01M | $30.77M |
| EBITDA | $18.54M | $43.87M |
| Pre-Tax Income | $13.11M | $43.72M |
| Income Tax | $3.83M | $11.43M |
| Net Income (Profit) | $9.27M | $32.29M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GRDN | NHC |
|---|---|---|
| Cash & Equivalents | $14.00M | $90.39M |
| Total Current Assets | $166.04M | $455.20M |
| Total Current Liabilities | $145.30M | $239.23M |
| Long-Term Debt | $21.79M | $163.31M |
| Total Shareholders Equity | $163.22M | $1.01B |
| Retained Earnings | $26.57M | $774.95M |
| Property, Plant & Equipment | $78.92M | $1.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GRDN | NHC |
|---|---|---|
| Operating Cash Flow | $20.61M | $47.95M |
| Capital Expenditures | $-5.81M | $-6.14M |
| Free Cash Flow | $11.75M | $33.12M |
| Debt Repayment | $-1.13M | $-3.00M |
| Common Stock Repurchase | N/A | $-1.72M |
Short Interest & Institutional Ownership Analysis
| Metric | GRDN | NHC |
|---|---|---|
| Shares Short | 536,606 | 259,597 |
| Short Ratio | 1.66 | 6.59 |
| Short % of Float | 0.04% | 0.03% |
| Average Daily Volume (10 Day) | 319,010 | 76,840 |
| Average Daily Volume (90 Day) | 397,023 | 73,717 |
| Shares Outstanding | 63.29M | 15.45M |
| Float Shares | 9.39M | 12.46M |
| % Held by Insiders | 0.61% | 0.19% |
| % Held by Institutions | 0.84% | 0.59% |
Dividend Analysis & Yield Comparison: Guardian Pharmacy vs National Healthcare
| Metric | GRDN | NHC |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.44 |
| Last 12-Month Dividend Yield | N/A | 2.30% |
| 3-Year Avg Annual Dividend | N/A | $2.36 |
| 3-Year Avg Dividend Yield | N/A | 0.75% |
| 3-Year Total Dividends | N/A | $7.08 |
| Ex-Dividend Date | N/A | Mar 28, 2025 |